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Abstract
Background: The literature on the neuropsychological profiles in Bipolar disorder (BD) depression is sparse. The
aims of the study were to assess the neurocognitive profiles in treatment-resistant, acutely admitted BD depression
inpatients, to compare the neurocognitive functioning in patients with BD I and II, and to identify the demographic
and clinical illness characteristics associated with cognitive functioning.
Methods: Acutely admitted BD I (n = 19) and BD II (n = 32) inpatients who fulfilled the DSM-IV-TR criteria for a
major depressive episode were tested with the MATRICS Consensus Cognitive Battery (MCCB), the Wechsler
Abbreviated Scale of Intelligence, the National Adult Reading Test, and a battery of clinical measures.
Results: Neurocognitive impairments were evident in the BD I and BD II depression inpatients within all MCCB
domains. The numerical scores on all MCCB-measures were lower in the BD I group than in the BD II group, with a
significant difference on one of the measures, category fluency. 68.4% of the BD I patients had clinically significant
impairment (>1.5 SD below normal mean) in two or more domains compared to 37.5% of the BD II patients
(p = 0.045). A significant reduction in IQ from the premorbid to the current level was seen in BD I but not BD II
patients. Higher age was associated with greater neurocognitive deficits compared to age-adjusted published
norms.
Conclusions: A high proportion of patients with therapy-resistant BD I or II depression exhibited global
neurocognitive impairments with clinically significant severity. The cognitive impairments were more common in
BD I compared to BD II patients, particularly processing speed. These findings suggest that clinicians should be
aware of the severe neurocognitive dysfunction in treatment-resistant bipolar depression, particularly in BD I.
Trial registration: NCT00664976
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Background
Bipolar disorder (BD) is associated with various cognitive
impairments, of which deficits in verbal learning, atten-
tion, and executive functions are the most frequently
reported [1-3]. The literature on the neuropsychological
profiles in BD depression is sparse [4-9]. Studies on cog-
nitive function have often not distinguished between BD
and recurrent depressive subgroups, or else they have in-
volved heterogeneous patient groups with BD in euthymic,
mixed, or unclassified mood states. A meta-analysis of
studies on cognitive function in euthymic, manic or
mixed, and depressed BD patients [10] revealed cognitive
impairments in all phases of the illness, across all neuro-
psychological domains, with a moderate worsening of a
subset of deficits in acute states.
BD I and BD II patients present with heterogeneous
clinical symptoms [11]. In contrast to the Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edition,
Text Revision (DSM-IV-TR) [12], BD II does not exist as a
specific diagnosis in the International Classification of Dis-
eases, Tenth Revision (ICD-10) [13]. There are arguments
for and against BD II as a distinct diagnostic entity [14].
Comparing the neuropsychological functioning between
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the BD I and BD II types of depression may provide indi-
cations of these putative different entities. Several studies
have compared cognitive functioning in euthymic BD I
and BD II patients [15-18], and deficits were found in both
groups. Most studies have found more cognitive deficits in
BD I patients, with the most prominent difference being
in memory function. However, in a limited number of BD
patients with current mood state euthymia or mild depres-
sion recruited from out-patient clinics or journal adver-
tisements, Summers and colleagues found that patients
with BD I performed better than those with BD II [19].
We are aware of only one study comparing the neuro-
psychological performance in depressed unipolar, BD I
and BD II patients [20]. Xu et al. found a similar pattern
of cognitive impairment in the three groups, with cogni-
tive dysfunction in processing speed, memory, verbal flu-
ency and executive functioning, but not attention. BD I
patients were more impaired than BD II and unipolar de-
pressed patients in verbal fluency and executive function.
There are indications of a possible neurodegenerative pro-
cess in BD [21]. More extensive cognitive impairment may
be associated with a more severe course of illness, includ-
ing a greater number of episodes, history of psychotic
symptoms, and longer duration of illness [22-24]. A previ-
ous study found a correlation between a reduction in IQ
and structural changes in BD [25].
Treatment resistant BD depression patients constitute
a significant proportion of inpatient samples. These pa-
tients represent a clinical challenge. Further research on
cognitive functioning may have impact on factors affect-
ing acute treatment and follow up.
Aims of the study
The main aims of the present study were to assess
the neurocognitive profiles in treatment-resistant, acutely
admitted BD depression inpatients, to compare the neu-
rocognitive functioning in patients with BD I and II, and
to identify the demographic and clinical illness character-
istics associated with cognitive functioning.
Methods
Study design
The data were collected in the Norwegian random-
ized controlled trial of electroconvulsive therapy in
acutely admitted, treatment-resistant BD inpatients.
The protocol for this trial has been published previ-
ously [26]. The neuropsychological functioning at
baseline was assessed after admittance to hospital but
before the start of treatment.
Subjects
The study participants comprised 51 patients who met
DSM-IV-TR [12] criteria for BD I (n = 19) or BD II (n = 32)
disorder. The diagnosis was made primarily on the basis of
a clinical interview supported by information from sig-
nificant others and hospital records, and subsequent-
ly verified by the Mini-International Neuropsychiatric
Interview (MINI; specifically the MINI-Plus) [27] or the
Structured Clinical Interview for DSM-IV Axis I Disor-
ders (SCID-I) [28]. The assessing psychiatrists had par-
ticipated in a structured training program for SCID-I or
MINI-Plus.
The patients fulfilled the DSM-IV-TR criteria of a de-
pressive episode [12]. The severity of depressive symp-
toms was assessed using the Montgomery and Åsberg
Depression Rating Scale (MADRS) [29], with a cut-off
score of ≥25 for participation in the study. All patients
were treatment resistant in terms of a nonresponse to
at least two lifetime trials with mood stabilizers with
proven efficacy in BD depression (lithium, lamotrigine,
quetiapine, and olanzapine) and/or antidepressants. A
trial was defined as a minimum of 6 weeks on an ad-
equate or tolerated dose as reported by the patient, or
for a shorter period when treatment was terminated
prior to 6 weeks due to side effects. Nonresponse was
defined as a reduction in MADRS scores of <50% or still
fulfilling DSM-IV-TR criteria of a depressive episode.
Patients had to be sufficiently fluent in Norwegian to
ensure valid responses to psychometric testing (i.e.,
Norwegian must be their primary language, or they must
have received their compulsory schooling in Norwegian).
The criteria for exclusion were treatment with elec-
troconvulsive therapy (ECT) within the previous 6
months or having been diagnosed with conditions that
may affect neuropsychological assessment, such as
Parkinson’s disease, multiple sclerosis, stroke, ongoing
alcohol or substance abuse, or other criteria as defined
in the protocol [26].
Assessment of symptoms
Symptom intensity was rated using the MADRS [29], the
Positive and Negative Syndrome Scale for Schizophrenia,
positive subscale (PANSS pos) [30], and the Global Assess-
ment of Functioning–Split version, symptom subscale
(GAF-S) [31]. Symptoms were assessed by trained clini-
cians (psychiatrists, psychologists, and psychiatric nurses).
Definition of illness characteristics
The patients were interviewed with the Norwegian adap-
tation of the Stanley Foundation Bipolar Collaboration
Network Entry Questionnaire (NEQ) used by the Bipolar
Collaboration Network [32-35]. The NEQ has 48 items
and covers a wide range of demographic and clinical fac-
tors describing the course of illness. Substance abuse
was defined as fulfilling the DSM-IV-TR criteria for life-
time abuse of alcohol, psychotropic medication, or illicit
substances. Psychosis was defined as lifetime admission
to hospital with a psychotic illness, as verified by the
Kessler et al. BMC Psychiatry 2013, 13:105 Page 2 of 10
http://www.biomedcentral.com/1471-244X/13/105
MINI-Plus or the SCID-I. Length of education was
quantified as the duration of completed education in
years. Previous serious suicide attempts were defined as
attempts that required medical attention, an emergency
room visit, or hospitalization [36].
Neuropsychological assessment
Neurocognitive assessment was carried out by clinical
psychologists or test assistants with training in standard-
ized neuropsychological testing. Current IQ was assessed
using the Wechsler Abbreviated Scale of Intelligence
(WASI) [37]. The National Adult Reading Test (NART)
[38] is designed to estimate the premorbid intelligence
in adults. Reading skills are significantly correlated with
Wechsler-based IQ scores and is relatively unaffected
by most nonaphasic brain disorders [39]. In the present
study, the premorbid IQ was estimated with a Norwegian
research version of the NART [40].
The Measurement and Treatment Research to Im-
prove Cognition in Schizophrenia (MATRICS) Consen-
sus Cognitive Battery (MCCB) [41] is designed for use in
clinical trials assessing cognitive function in schizophre-
nia and related psychiatric disorders [42]. Although there
is no established standard battery specifically designed to
assess cognition in BD, recent papers [43,44] support the
use of MCCB in BD research. The neuropsychological
profile (consisting of the six neurocognitive domains,
I–VI, listed below) was assessed using the following nine
tests from the Norwegian version [45] of the MCCB [41]:
I. Speed of processing:
1. Brief Assessment of Cognition in Schizophrenia
(BACS): Symbol Coding (total number correct).
2. Category Fluency: Animal Naming (total number
of animals named in 60 seconds).
3. Trail-Making Test: part A (TMT-A): (time to
completion).
II. Attention/Vigilance:
4. Continuous Performance Test-Identical Pairs
(CPT-IP): (mean d’ value across two-, three-, and
four-digit conditions, where d’ is an index of
signal–noise discrimination).
III. Working memory:
5. Wechsler Memory Scale–third edition (WMS-III):
Spatial Span (sum of raw scores on the forward
and backward conditions).
6. Letter-Number Span: (total number correct).
IV. Verbal learning:
7. Hopkins Verbal Learning Test–Revised (HVLT-R):
(total number of words recalled correctly over
three learning trials).
V. Visual learning:
8. Brief Visuospatial Memory Test–Revised (BVMT-R):
(total recall score over three learning trials).
VI. Reasoning and problem solving:
9. Neuropsychological Assessment Battery (NAB):
mazes (total raw score).
Raw scores from each of the nine administered MCCB
tests were converted into standardized T-scores with a
mean of 50 and standard deviation of 10, based on age-
and gender-corrected norms from the MCCB manual
[42]. The T-scores for the six assessed domains were
used to compute a mean neurocognitive composite
score. Nine patients had missing scores in one, and one
patient in two of the tested domains. For these ten sub-
jects, the mean composite score was computed based on
the remaining domain T-scores.
Statistical analysis
Characteristics for the BD I and BD II patients were
compared using t-tests and analysis of variance for con-
tinuous, and chi-square test for categorical variables.
Statistical comparisons between BD subtypes for non-
normally distributed variables were performed with a
Mann-Whitney Test. Correlation and multiple linear re-
gression analyses were performed between neuropsycho-
logical measures and demographic variables (gender,
age, education, and premorbid IQ), course of illness (BD
subtype, duration of illness, number of hospitalizations
due to depressive episodes, number of psychotic epi-
sodes, history of psychosis, comorbid substance abuse,
and comorbid anxiety), and current symptoms (MADRS,
PANSS pos, GAF-S). Due to the small number of pa-
tients relative to the large number of independent vari-
ables, analyses were conducted unadjusted, and adjusted
for age and education only. The level of statistical sig-
nificance was set at p < 0.05. All statistical analyses were
performed using the Statistical Package for the Social
Sciences (version 18.0, SPSS, Chicago, IL, USA).
Ethics
The study was approved by The Regional Committee for
Research Ethics, Central Norway, and The Norwegian Data
Inspectorate. The study is registered in the online clinical
database ClinicalTrials.gov (identifier NCT00664976). All
subjects provided informed written consent to participate
prior to their inclusion in the study.
Results
Demographic characteristics
The demographic characteristics of the BD I and BD II
patients are listed in Table 1. The BD I group had a
shorter duration of education and comprised more pa-
tients with a history of psychosis compared to the BD II
group. The estimated premorbid IQ did not differ be-
tween the groups, both of which performed in the
“above normal” range. The scores on the rating scales
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used to assess symptom severity did not differ between
the groups.
Two patients reported an alcohol consumption of more
than 3 units/day (where 1 unit = approximately one glass
of wine or one bottle of beer), and four reported spora-
dic use of amphetamine, heroin, or cannabis during the
6 months preceding inclusion. Previous serious suicide at-
tempts were reported by 56%, with no significant differ-
ence between the groups.
At admittance, 64% of the patients used second-
generation antipsychotics, 50% used antiepileptics, 74%
used antidepressants, 30% used lithium, 48% used ben-
zodiazepines, 86% used a psychotropic combination, and
6% used no psychotropic medication; these proportions
did not differ significantly between the groups.
Neurocognitive profile
Age- and gender-corrected T-scores for the nine cogni-
tive MCCB tasks, the six domain scores and mean
composite score, current IQ assessed using the WASI,
and decrease in IQ from the estimated premorbid IQ
assessed using the NART, are listed in Table 2. The nu-
merical scores on all measures were lower in the BD I
group than in the BD II group, but the difference was
significant on only one of the measures, category flu-
ency. The effect sizes for these differences are classified
as small to medium [46]. The performance on the WASI
was significantly worse for the BD I patients than for the
BD II patients. This indicates a decline in IQ in the BD I
patients from the premorbid to the current level. The IQ
declines in the BD I and BD II groups were 18.0 and 6.1,
respectively (p < 0.01). The effect sizes for the differences
in current IQ and IQ decline are both classified as large.
The MCCB profiles for the six cognitive domains in
the BD I and BD II groups indicate neurocognitive func-
tioning at a level between 1 and 1.5 SD below nor-
mal means across domains. The performances in both
groups were significantly below the normal means for all
domains. Patients obtaining scores lower than 1.5 SD
below the normal mean (i.e., T ≤ 35) are classified as
clinically impaired. The percentages of patients with im-
pairment in the different domains are listed in Table 3.
The percentage of impaired patients was higher in the
BD I group than in the BD II group, with significant dif-
ferences in speed of processing, current IQ, and IQ de-
cline. Clinically impairment was more common among
BD I patients: the percentage of BD I and BD II patients
with neurocognitive impairments in two or more do-
mains were 68.4% and 37.5%, respectively (chi-square
test: p = 0.045).
Influence of demographic and illness characteristics on
cognitive functioning
The associations between demographic and illness char-
acteristics and cognitive measures are listed in Table 4.
We found a significant correlation between age and test
performance. The expected cognitive decline associated
with normal aging was accounted for by using age-
Table 1 Clinical characteristics of bipolar disorder (BD) inpatients with therapy-resistant depression
Variable Total
sample
BD I BD II p
n = 19 n = 32
Demographics Gender (male), n (%) 24 (47.1) 7 (36.8) 17 (53.1) 0.201)
Age (years) 45.7 (10.5) 49.2 (9.2) 43.6 (10.8) 0.062)
Education (years) 13.8 (3.2) 12.6 (3.2) 14.5 (3.0) 0.042)
Premorbid IQ 112.9 (3.7) 112.0 (3.9)a 113.5 (3.4)b 0.182)
Course of illness Duration of illness (years) 30.6 (11.4) 33.4 (9.4)a 29.1 (12.2) 0.192)
Hospitalizations due to depressive episodes 4.3 (3.9) 4.7 (4.8)c 4.1 (3.5)d 0.823)
History of psychotic symptoms, n (%) 24 (48.0) 16 (84.2) 8 (25.8)e <0.011)
Number of psychotic episodes 1.8 (3.0) 3.6 (3.6)c 0.8 (2.1)f <0.013)
Lifetime DSM-IV-TR diagnosis Substance abuse, n (%) 15 (29.4) 6 (31.6) 9 (28.1) 1.001)
Anxiety, n (%) 14 (29.2) 8 (47.1)g 6 (19.4)e 0.061)
Symptom rating scales MADRS 37.0 (6.6) 36.8 (6.6) 37.2 (6.6) 0.872)
PANSS pos 9.8 (3.4) 9.7 (3.6)c 9.8 (3.4) 0.763)
GAF-S 37.3 (10.9) 41.0 (9.8)a 35.3 (11.1) 0.103)
Data are mean (SD) values unless otherwise specified for total group and groups with BD I or BD II subtype, accompanied by p values for statistical comparisons
between subtypes: 1)chi-square test; 2)independent-samples t-test; 3)Mann-Whitney Test. Data presented in bold, p < 0.05.
SD, Standard deviation; MADRS, Montgomery and Åsberg depression rating scale; PANSS pos, Positive and negative syndrome scale for schizophrenia, positive
subscale; GAF-S, Global assessment of functioning–split version, symptom subscale; DSM-IV-TR, Diagnostic and statistical manual of mental disorders, fourth
edition, text revision.
an = 18, bn = 28, cn = 15, dn = 30, en = 31, fn = 29, gn = 17.
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adjusted T-scores. Higher age was associated with an in-
creased difference from the normal mean (T = 50). The re-
lationship between the mean composite score and age is
shown in Figure 1. Age and education strongly influenced
test performance, and these two variables were controlled
for in a multiple linear regression analysis. Neither course
of illness (diagnostic subtype, number of hospitalizations
due to depressive episodes, number of psychotic episodes,
history of psychosis, comorbid substance abuse, and co-
morbid anxiety disorder) nor level of symptoms (MADRS,
PANSS pos, and GAF-S scores) were associated with over-
all cognitive function (mean composite score) or the six
cognitive domains when controlled for age and education
(details not shown). Diagnostic subtype BD I (b = 9.2,
p = 0.02) and history of psychosis (b = 9.1, p = 0.01) were
associated with a greater IQ decline when controlled for
age and education, whereas longer duration of illness was
negatively associated to IQ decline (b = -0.9, p = 0.002)
when controlled for age and education.
Discussion
The present findings indicate that patients with therapy-
resistant BD depression exhibit reduced performance in
all of the cognitive domains assessed by the MATRICS
battery. Almost half of the patients were impaired in two
or more domains, indicating that cognitive deficits are
relatively common and non-specific in BD depression.
We found that speed of processing and verbal learning
were the most frequently and severely affected domains.
Speed of processing was also found to be the most se-
verely affected domain in a study using the MCCB in
euthymic and symptomatic BD I patients [44]. There is
only one test in the MCCB assessing executive function-
ing; mazes. That may explain why both in the current
study and in the study by Burdick et al. executive func-
tioning seemed to be less impaired than previously
reported [47].
In the present study, the percentage of patients with
clinically significant cognitive impairment varied across
Table 2 Test performance (T-scores) for the total sample, BD I and BD II subsamples in inpatients with therapy-resistant BD
depression on nine cognitive tasks from the MCCB, six domain scores and mean composite score, and IQ, and change in IQ
from the estimated premorbid level
Neurocognitive domain Total sample BD I BD II ANOVA
Test n = 51 n = 19 n = 32 F p η2
Mean (SD) Mean (SD) Mean (SD)
Speed of processing 36.5 (12.3) 32.3 (14.6) 39.0 (10.2) 3.69 0.061) 0.07
BACS–Symbol Coding 37.0 (11.7) 35.0 (13.6) 38.2 (10.5) 0.672)
Fluency 44.7 (9.5) 40.7 (10.5) 47.1 (8.1) 5.91 0.021) 0.11
TMT-A 37.7 (13.1) 33.7 (13.5) 40.0 (12.6) 2.77 0.101) 0.05
Attention/Vigilance 40.7 (11.4)a 38.5 (11.8)b 41.8 (11.3)c 0.78 0.381) 0.02
CPT
Working memory 43.5 (11.2) 41.2 (11.1) 45.0 (11.3) 1.37 0.251) 0.03
Spatial Span 45.9 (10.6)d 44.2 (10.8) 47.0 (10.5)e 0.80 0.381) 0.02
Letter-Number Span 43.5 (10.7) 41.2 (10.7) 44.9 (10.7) 1.45 0.241) 0.03
Verbal learning 38.4 (8.1) 36.5 (7.6) 39.5 (8.2) 1.73 0.191) 0.03
HVLT-R
Visual learning 43.0 (11.7)f 40.7 (13.7)g 44.3 (10.4)h 1.04 0.311) 0.02
BVMT-R
Reasoning 42.3 (9.3)d 41.9 (7.8)g 42.4 (10.1) 0.812)
Mazes
Mean composite score 40.6 (8.4) 38.4 (9.3) 41.9 (7.7) 2.19 0.141) 0.04
IQ 102.3 (13.6) 93.9 (15.2) 107.2 (10.2) 14.05 <0.011) 0.22
WASI
IQ difference 10.8 (13.0)i 18.0 (13.7)g 6.1 (10.3)j 11.29 <0.011) 0.20
NART-WASI
Note: Scores on the MCCB measures have a mean of T = 50 and an SD of T = 10. IQ scores have a mean of 100 and an SD of 15. p values for statistical
comparisons between BD subtypes: 1)ANOVA; 2)Mann-Whitney Test. Data presented in bold, p < 0.05.
MCCB, Measurement and treatment research to improve cognition in schizophrenia (MATRICS) consensus cognitive battery; ANOVA, Analysis of variance; BACS,
Brief assessment of cognition in schizophrenia; TMT-A, Trail-making test, part A; CPT, Continuous performance test; HVLT-R, Hopkins verbal learning test–revised;
BVMT-R, Brief visuospatial memory test–revised; WASI, Wechsler abbreviated scale of intelligence; NART, National adult reading test.
an = 44, bn = 14, cn = 30, dn = 50, en = 31, fn = 49, gn = 18, hn = 31, in = 46, jn = 28 due to missing data.
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domains and measures, but it was higher than previously
reported for stable outpatients [16]. Clinically significant
cognitive impairment, defined as ≥1.5 SD below the con-
trol group mean, was reported for 24% of BD I and 13%
of BD II outpatients [16], versus 42% and 25%, respect-
ively, in the present study. This difference may be attribut-
able to the specific group of treatment-resistant, acutely
admitted depressed inpatients.
With scores on cognitive measures 1-1.5 SD below
normal mean the patients in the current sample experi-
enced somewhat greater cognitive deficits than described
in euthymic [47,48], or depressive state [8]. Although
the patients in the current study tended to perform
slightly weaker than reported from other patient sam-
ples, we did not find substantial differences in the cogni-
tive profile. This is in line with the findings from Kurtz
and Gerraty [10], describing reduced cognitive function
in all phases of BD, across all neuropsychological do-
mains, and a moderate deterioration of some measures
in acute state.
Previous findings from mainly euthymic BD patient
populations indicate a significant difference in cognitive
performance between BD I and BD II patients, with BD
I patients being more affected [15,16]. The present study
yielded a similar trend but it was not statistically signifi-
cant—this may have been due to the sample size.
The BD patients did not exhibit impairment in pre-
morbid IQ, which is consistent with previous findings
[49]. We found a significant difference in IQ decline be-
tween BD I and BD II patients, with 33% and 4%, re-
spectively, showing a decline in IQ of at least 1.5 SD
(22.5 points). The findings of the present study suggest
that there are neurobiological differences between BD I
and BD II. We are not aware of any other reports of a
similar IQ decline restricted mainly to the BD I popula-
tion. However, one study involving euthymic and de-
pressed outpatients [19] found an IQ decline in 2 out of
11 BD II patients and none of the BD I patients. These
conflicting results might be due to differences in patient
recruiting; whereas the present study assessed treatment
resistant BD patients in a major depressive episode,
Summers and colleagues evaluated euthymic and mildly
depressed patients recruited from out-patient clinics and
through journal advertisements.
A total of 48% of the patients in the present study had
experienced prior psychotic episodes (84% of BD I pa-
tients and 26% of BD II patients). The impact of the
prior psychotic symptoms on cognitive measures in BD
Table 3 Percentage of patients with cognitive impairment* for the total sample of 51 inpatients with therapy-resistant
BD depression, BD I, and BD II on nine cognitive tasks from the MCCB, six domain scores and mean composite score,
and IQ and change in IQ from the estimated premorbid level
Neurocognitive domain Total sample BD I BD II BD I vs. BD II
Test n = 51 n = 19 n = 32 χ2 p
Speed of processing 43.1 63.2 31.2 4.9 0.041
BACS–Symbol Coding 49.0 52.6 46.9 0.2 0.776
Fluency 17.6 31.6 9.4 4.0 0.062
TMT-A 45.1 63.2 34.4 4.0 0.080
Attention/Vigilance 36.4a 42.9 33.3 0.4 0.738
CPT
Working memory 21.6 21.1 21.9 0.0 1.000
Spatial Span 18.0b 26.3 12.9 1.4 0.273
Letter-Number Span 25.5 31.6 21.9 0.6 0.515
Verbal learning 39.2 42.1 37.5 0.1 0.774
HVLT-R
Visual learning 24.5c 38.9 16.1 3.2 0.094
BVMT-R
Reasoning 30.0b 22.2 34.4 0.8 0.523
Mazes
Mean composite score 31.4 42.1 25.0 1.6 0.228
IQ 5.9 15.8 0.0 5.4 0.047
WASI
IQ decline (NART-WASI) ≥1.5 SD 15.2d 33.3 3.6 7.5 0.010
*Defined as at least 1.5 SD below the normal mean.
an = 44, bn = 50, cn = 49, dn = 46 due to missing data.
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Table 4 Correlations between demographic and illness characteristics and neurocognitive performance for the total sample of 51 inpatients with therapy-resistant
BD depression
Neurocognitive
domain
Demographic characteristics Course of illness Current symptoms
Gender
(male)
Age Education Premorbid IQ BD I Duration
of illness
Number of
hospitalizations
due to
depresssive
episodes
History of
psychotic
symptoms
Number
of
psychotic
episodes
Comorbid
substance
abuse
Comorbid
anxiety
MADRS PANSS
pos
GAF-S
Test (NART)
Speed of Processing −0.09 −0.21 0.25 0.20 −0.25 −0.12 −0.02 −0.14 −0.10 0.09 0.02 0.05 −0.01 −0.05
BACS–Symbol Coding −0.19 −0.29* 0.28 0.27 −0.06 −0.27 −0.14 −0.04 0.01 0.08 0.17 −0.06 −0.15 0.06
Fluency −0.09 −0.11 0.20 0.06 −0.35* 0.10 0.22 −0.20 −0.24 0.01 0.05 −0.01 −0.05 0.17
TMT-A −0.02 −0.19 0.23 0.14 −0.22 −0.15 −0.11 −0.09 −0.11 −0.01 −0.09 0.11 0.09 −0.22
Attention/Vigilance −0.20 −0.46** 0.14 0.00 −0.11 −0.43** −0.29 −0.08 −0.10 0.23 0.20 −0.19 −0.06 −0.10
CPT
Working memory −0.17 −0.43** 0.36** 0.16 −0.13 −0.27 −0.01 −0.07 −0.07 0.04 0.19 0.01 −0.20 0.05
Spatial Span −0.10 −0.42** 0.27 0.13 −0.12 −0.21 0.09 0.07 0.08 0.12 0.32 0.10 −0.20 0.00
Letter-Number Span −0.17 −0.38** 0.37** 0.16 −0.11 −0.31* −0.10 −0.20 −0.20 −0.05 0.05 −0.05 −0.15 0.06
Verbal learning −0.04 −0.37** 0.32* 0.36* −0.14 −0.25 −0.05 −0.20 −0.14 0.05 0.01 0.00 −0.25 0.02
HVLT-R
Visual learning −0.09 −0.28 0.34 0.16 −0.21 −0.14 0.17 −0.17 −0.12 0.12 0.23 −0.04 −0.14 0.03
BVMT-R
Reasoning −0.21 −0.19 0.22 0.04 0.04 −0.06 −0.13 0.10 0.08 0.18 0.21 0.07 0.02 −0.04
Mazes
Mean Composite score −0.18 −0.40** 0.36** 0.22 −0.19 −0.26 −0.07 −0.13 −0.12 0.10 0.15 −0.02 −0.13 −0.04
IQ-decline −0.21 0.17 −0.41** −0.17 0.43** −0.05 0.17 0.40** 0.41* −0.17 −0.01 0.05 0.26 −0.17
NART-WASI
Spearman’s rho is reported. *p < 0.05; **p < 0.01.
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has been investigated in several studies, and a meta-
analysis [24] concluded that a prior history of psychotic
symptoms is associated with increased impairments in
several cognitive domains. We found an association be-
tween the number of previous psychotic episodes and IQ
decline from premorbid to current levels. However, we
did not find an association between the number of psych-
otic episodes and MCCB scores. We found a negative cor-
relation between illness duration and IQ decline when we
controlled for age and education. This might be due to lar-
ger IQ decline for patients with an older age at onset.
Studies of associations between depression severity and
cognitive impairment in BD have produced contradictory
results, with one study [50] finding that mildly depressed
patients performed better on cognitive tasks than severely
depressed patients, whereas studies involving outpatients
[51] or mainly euthymic BD I patients [52] found no re-
lationship between cognitive measures and depressive
symptoms. The present findings indicate that cognitive
impairments were correlated more strongly with age and
education than with symptom severity in inpatients with
treatment-resistant BD depression. The non-significant
correlation between symptom severity and cognitive im-
pairment in this study might be due to small variance,
since all the participants were severely affected.
There is a cognitive decline in normal aging. This was
accounted for by using age-adjusted T-scores. The pre-
sent cross sectional findings of the cognitive deficits
increasing with age are consistent with a longitudinal
study documenting a greater cognitive decline over 3 years
in older BD patients compared to healthy controls with the
same age and education [53], whereas a study of 65
euthymic elderly outpatients with BD revealed poorer cog-
nitive function than normal controls but no faster cognitive
decline over 2 years [54]. This might partly be due to the
relatively short interval between the two assessments. We
suppose that our findings of larger cognitive deficits in
older patients represent an age-related, accelerated cogni-
tive decline, which may be a consequence of an ongoing
neurodegenerative process in a subgroup of BD patients
[21]. The present cross-sectional study does not indicate
whether the described deficits are limited to the major de-
pression or persist at the same magnitude into remission.
It cannot be excluded that our finding of an age-related
increased cognitive deficit in BD patients with severe de-
pression is state dependent, and not indicative of a general
age-related reduced cognitive capacity in euthymic BD.
Our findings could indicate that older BD patients are
more vulnerable to the development of cognitive deficits
when depressed, possibly as a result of a reduced capacity
to maintain cognitive functioning in a state of depression.
The present sample of highly selected, treatment-
resistant patients might not be representative of less se-
verely affected BD patients. Patients in this study may
belong to a subgroup with progressive cognitive decline.
The results of this study indicate a strong association
between age and cognitive deficits, but no association with
any of the illness characteristics. The stronger influence of
age compared to illness characteristics on cognitive func-
tioning might reflect patients’ difficulties in recalling their
illness history. Another possible explanation for our find-
ing of a stronger influence of age than any of the illness se-
verity measures could be that BD per se—independently
from clinical factors—results in a greater vulnerability to
age-related pathological processes.
The present study was subject to some limitations.
Since it had a cross-sectional design, the relationship be-
tween age and accelerated cognitive decline should be
confirmed in a longitudinally designed study. Although
there are possible confounding effects from previous and
current use of psychotropic medications, the medication
at admittance did not differ significantly between the
two groups. The sample size in our study limits both the
use of regression models and the probability to detect
possible significant differences in MCCB-scores between
the bipolar subtypes (type II error); therefore, the nega-
tive findings of this study should be confirmed by larger
studies. Data on the course of illness, such as the num-
ber of previous episodes, were collected retrospectively.
Even if the data were supplied by information from signifi-
cant others and hospital records there might have been a
recollection bias. A selection bias might have been present
due to recruitment through the Norwegian ECT study. All
patients had to accept possible randomization to ECT
and may therefore not be representative of all patients
with treatment-resistant BD depression. In the present
cross-sectional study the influence of the mood state on
cognitive functions in BD was not examined. Further
Figure 1 Relationship between mean composite T-score and
age for 51 inpatients with treatment-resistant depression in
bipolar disorder. Note: The mean composite score is based on six
domain scores from nine cognitive tasks from the MATRICS
Consensus Cognitive Battery.
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studies examining cognitive performance during illness
episodes and in remission are warranted to address this
issue.
The present study also has particular strengths: all par-
ticipating study centers included patients from their de-
fined catchment areas, all Norwegian acute psychiatric
services are public and available to everyone, and all of
the patients in the catchment areas were admitted to the
local study center.
Cognitive impairment in BD depression must be ad-
dressed in clinical practice. Patients with cognitive im-
pairments as described in the present study will probably
experience difficulties in situations that demand rapid
processing of information such as following complex in-
structions, sustaining attention, and remembering new
information. This may result in problems dealing with
practical tasks in daily life, work, maintaining social rela-
tionships, and treatment adherence. Neuropsychological
functioning should be assessed routinely in BD depres-
sion in order to identify particular strengths and difficul-
ties for the individual patient and adapt therapeutic
strategies.
Conclusions
A high proportion of patients with therapy-resistant BD
I or II depression exhibited global neurocognitive im-
pairments with clinically significant severity. The cogni-
tive impairments were more common in BD I compared
to BD II patients, particularly processing speed. These
findings suggest that clinicians should be aware of the
severe neurocognitive dysfunction in treatment-resistant
bipolar depression, particularly in BD I.
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